找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: GISTs - Gastrointestinal Stromal Tumors; Elisabetta Lutio di Castelguidone,Antonella Messin Book 2011 Springer Verlag Milan 2011 Gastroint

[复制链接]
楼主: 人工合成
发表于 2025-3-26 23:25:44 | 显示全部楼层
https://doi.org/10.1007/978-3-531-91112-0umerous radiologic techniques, such as conventional radiography, ultrasonography with and without color Doppler, contrast-enhanced ultrasound (CEUS), CT, MR and CT/PET, as well as endoscopic techniques such as endoscopy and endoscopic ultrasound (EUS).
发表于 2025-3-27 02:08:26 | 显示全部楼层
发表于 2025-3-27 07:43:31 | 显示全部楼层
发表于 2025-3-27 13:12:17 | 显示全部楼层
发表于 2025-3-27 13:58:23 | 显示全部楼层
发表于 2025-3-27 18:07:17 | 显示全部楼层
https://doi.org/10.1007/978-3-531-92178-5ance (MR). MR can be used In the Identification, characterization and staging of GISTs, as well as In the evaluation of response to treatment, showing the tissue changes Induced In cancer cells by molecular targeted therapies, Including myxohyaline changes, fibrosis, hemorrhagic necrosis and cellula
发表于 2025-3-28 01:34:38 | 显示全部楼层
https://doi.org/10.1007/978-3-658-17041-7of the pharmacological response to Imatinib Mesylate and it is specific in the follow-up of metastatic disease..In 2004, Choi demonstrated that the information deriving from Multidetector CT (MDCT) and PET are complementary in the evaluation of GIST’s response to medical treatment. He showed a corre
发表于 2025-3-28 05:55:07 | 显示全部楼层
"Von Pol zu Pol Gesänge sich erneun..."to oncogene mutations, they can be targeted effectively by anti-tyrosine kinase agents. Currently, In the first-line therapy of advanced GISTs, imatinib has brought median survival from around one to 5 years. Tumor response rate Is high and predictable through the mutational status of the disease. I
发表于 2025-3-28 08:57:57 | 显示全部楼层
发表于 2025-3-28 12:10:57 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-5-19 01:01
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表